An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Phase of Trial: Phase II/III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Padsevonil (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB Biopharma
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.
- 08 Jun 2018 Planned End Date changed from 22 Apr 2026 to 22 Mar 2023.
- 08 Jun 2018 Planned primary completion date changed from 22 Apr 2026 to 1 Jul 2022.